Suchergebnisse - "Zhu, Sha"

PubPharm (8)

1

Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Xu, N. | Zhao, J. | Zhao, F. | +26

2

Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Xu, N. | Zhao, J. | Zhao, F. | +26

3

Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Xu, N. | Zhao, J. | Zhao, F. | +26

4

The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer

enthalten in: The Prostate | 2021

von Wang, Z. | Zhu, S. | Zhao, J. | +18

5

Clinical and oncologic findings of extraprostatic extension on needle biopsy in de novo metastatic prostate cancer

enthalten in: Asian journal of andrology | 2020

von Chen, J. | Zhao, J. | Zhu, S. | +6

6

Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells

enthalten in: Aging | 2019

von Zhu, S. | Min, Z. | Qiao, X. | +8

7

AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy

enthalten in: The Prostate | 2019

von Zhao, J. | Zhang, M. | Liu, J. | +19

8

Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer

enthalten in: PloS one | 2014

von Zhu, S. | Oremo, J. | Li, S. | +3

1
[1]